We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

108 hedge funds and large institutions have $378M invested in BioXcel Therapeutics in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 37 increasing their positions, 32 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 32

0.13% more ownership

Funds ownership: 2.8% → 2.93% (+0.13%)

7% less funds holding

Funds holding: 116 → 108 (-8)

20% less capital invested

Capital invested by funds: $475M → $378M (-$96.5M)

25% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 32

38% less call options, than puts

Call options by funds: $4.94M | Put options by funds: $7.94M

Holders
108
Holders Change
-8
Holders Change %
-6.9%
% of All Funds
1.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
37
Reduced
32
Closed
32
Calls
$4.94M
Puts
$7.94M
Net Calls
-$3M
Net Calls Change
-$3.83M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$30.2M
2
AS
Altshuler Shaham
Israel
+$9.34M
3
CCM
CAAS Capital Management
New York
+$7.91M
4
GCM
Ghisallo Capital Management
Massachusetts
+$7.67M
5
State Street
State Street
Massachusetts
+$6.24M

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$17.3M
2
FLAM
First Light Asset Management
Minnesota
-$15.5M
3
LCG
Lisanti Capital Growth
New York
-$4.01M
4
CM
Caption Management
Oklahoma
-$1.73M
5
ACA
Apis Capital Advisors
New York
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
SWM
101
Spire Wealth Management
Virginia
$4K +$4.36K +8 New
GAM
102
Gemmer Asset Management
California
$3K – – –
LWANC
103
Laurel Wealth Advisors (North Carolina)
North Carolina
$3K – – –
APC
104
Aspire Private Capital
North Carolina
$3K +$3.27K +6 New
TWA
105
TCI Wealth Advisors
Arizona
$2K +$2.18K +4 New
FDCDDQ
106
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.16K +$1.64K +3 New
Northwestern Mutual Wealth Management
107
Northwestern Mutual Wealth Management
Wisconsin
$1K +$1.09K +2 New
AIG
108
American International Group
New York
$249 +$37.6K +69 +15%
LGM
109
Logos Global Management
California
– -$17.3M -25,000 Closed
FLAM
110
First Light Asset Management
Minnesota
– -$15.5M -22,402 Closed
LCG
111
Lisanti Capital Growth
New York
– -$4.01M -5,814 Closed
CM
112
Caption Management
Oklahoma
– -$1.73M -2,500 Closed
ACA
113
Apis Capital Advisors
New York
– -$1.55M -2,250 Closed
California Public Employees Retirement System
114
California Public Employees Retirement System
California
– -$1.03M -1,488 Closed
Thrivent Financial for Lutherans
115
Thrivent Financial for Lutherans
Minnesota
– -$893K -1,294 Closed
MAP
116
Moody Aldrich Partners
Massachusetts
– -$874K -1,265 Closed
Allianz Asset Management
117
Allianz Asset Management
Germany
– -$768K -1,112 Closed
PAM
118
Panagora Asset Management
Massachusetts
– -$745K -1,079 Closed
CSS
119
Cubist Systematic Strategies
Connecticut
– -$660K -956 Closed
Millennium Management
120
Millennium Management
New York
– -$630K -912 Closed
AQR Capital Management
121
AQR Capital Management
Connecticut
– -$376K -544 Closed
LC
122
Longitude (Cayman)
Cayman Islands
– -$345K -500 Closed
Victory Capital Management
123
Victory Capital Management
Texas
– -$326K -473 Closed
LPL Financial
124
LPL Financial
California
– -$269K -390 Closed
BAM
125
Blueshift Asset Management
New Jersey
– -$257K -373 Closed
2 3 4
5
6

BTAI Hedge Fund Activity: Q2 2021 in Review

108 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2021, worth a combined $378M — down 20% from $475M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of BTAI and 24 opened new positions — a net loss of 8 holders — while 32 trimmed existing stakes and 37 added.

The largest buyer was Fidelity Investments, adding an estimated $30.2M. The largest seller was Logos Global Management, exiting entirely with an estimated $17.3M sold.

  • 108 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2021, down from 116 in Q1 2021.
  • Funds reported $378M of BioXcel Therapeutics stock for Q2 2021, down 20% quarter-over-quarter.
  • 24 funds opened new BioXcel Therapeutics positions in Q2 2021 and 32 closed out, a net change of -8 holders.
  • The largest BioXcel Therapeutics buyer in Q2 2021 was Fidelity Investments, an estimated $30.2M added.
  • The largest BioXcel Therapeutics seller in Q2 2021 was Logos Global Management, an estimated $17.3M sold.

Based on aggregated 13F filings for Q2 2021.